Lactobacillus paracasei CBA L74 Supernatant for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The intestinal immune system, particularly in infants and the elderly, is immature or declines with age, leading to increased susceptibility to gastrointestinal disorders such as infections, food allergies, and inflammatory bowel diseases, with current probiotic compositions not fully addressing the need for therapeutic strategies to promote gastrointestinal health.
Innovation Solution
A composition comprising the supernatant of a fermented culture of Lactobacillus paracasei CBA L74, which includes sub-cellular bacterial components, is used to stimulate the mucosal immune system and treat gastrointestinal disorders, including those associated with immune system immaturity, food allergies, and inflammatory bowel diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If probiotic compositions are used to stimulate the mucosal immune system, then immune system function is improved, but the compositions are ineffective in individuals with immature or declining immune systems
Solution Approach 1:
The patent extracts and isolates specific immunomodulatory components (supernatant, cell wall extracts, metabolites) from the probiotic bacterium Lactobacillus paracasei CBA L74. By separating these active components from the whole organism, the composition can specifically target and stimulate the mucosal immune system in a manner that is effective even for immature or declining immune systems, resolving the contradiction between reliability and adaptability.
2Reliability
If the intestinal immune system is stimulated to respond to pathogens, then protective immune responses are enhanced, but immune responses against food antigens and beneficial materials increase
Solution Approach 1:
The patent targets the stimulation specifically to the mucosal immune system through localized delivery of L. paracasei CBA L74 components. By focusing the immunomodulatory effect on the intestinal mucosa rather than systemically, the composition enhances protective responses to pathogens while minimizing excessive immune responses against food antigens and beneficial materials, thus resolving the contradiction between protective immunity and harmful immune reactions.
3Reliability
If probiotic compositions are administered to treat gastrointestinal disorders, then treatment effectiveness is improved, but the compositions do not address immune system immaturity
Solution Approach 1:
The patent changes the parameters of the probiotic composition by using L. paracasei CBA L74, which has been specifically shown to stimulate the mucosal immune system. The composition includes supernatant, cell wall extracts, and metabolites that have demonstrated ability to enhance immune function in both immature and declining immune systems, making the treatment effective across different age groups and immune states, thus resolving the contradiction between treatment effectiveness and adaptability to immune system immaturity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Lactobacillus paracasei CBA L74 supernatant composition effectively modulates pro- and anti-inflammatory markers, enhances the intestinal immune response, and provides immunomodulatory effects, reducing symptoms of gastrointestinal disorders and improving immune system function.
Implementation Method 1
a supernatant of a fermented culture of the probiotic bacterium Lactobacillus paracasei CBA L74
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
The present invention features compositions and methods for modulation of the mucosal immune system. The compositions include foods fermented by the probiotic organism, Lactobacillus paracasei CBA L74 (International Depository Accession Number LMG P-24778). Alternatively the compositions can include L. paracasei CBA L74 and a physiologically acceptable carrier. In some embodiments, the L. paracasei CBA L74 can be non-replicating. The compositions can be administered to a subject having or at risk for gastrointestinal disorders related to immaturity of the immune system, infection or disease.